Germany advises against moderna shots for young people with rare heart disease

Following other European countries on Wednesday, German health officials advised people under the age of 30 not to use Moderna’s Spikevax COVID-19 vaccine after evidence was revealed.

A German advisory board, known as STIKO, cited findings similar to a study published by Epi-Phare in France on November 8, and a vaccine using mRNA technology was hospitalized for myocarditis (heart inflammation). It has been shown to be associated with increased risk. Younger patients had pericarditis (inflammation of the tissues surrounding the heart), and those who received Moderna had a slightly higher prevalence.

STIKO to Germans in this age group Only the BioNTech / Pfizer vaccine should be given as it causes less heart inflammation. The Commission also recommended that pregnant women, regardless of age, receive only the BioNTech / Pfizer vaccine.

STIKO does not mention AstraZeneca and Johnson & Johnson’s COVID-19 vaccine.

German health officials CCP (Chinese Communist Party) virus Next day vaccination guidance Also recommended by French health authorities Due to similar heart disease concerns, Pfizer jabed Moderna.According to the translated statement, they emphasized that the risk of developing heart disease is “very rare.” Post About the French National Department of Health (HAS).

Recommendations in Germany are based on new safety data from the Paul Ehrlich Institute (PEI), the national authority responsible for vaccines, as well as new international data.

German PEI data showed a “report rate” of 11.71 cardiac inflammation per 100,000 shots with the Moderna vaccine in men aged 18-29 years, compared to 4.68 for BioNTech / Pfizer shots. For women, the rate was 2.95 for Moderna and 0.97 for BioNTech / Pfizer.

In the 12-17 year old group, the proportion of males with Moderna shots was 11.41 compared to 4.81 for BioNTech / Pfizer. No data is provided for younger women.

On Tuesday, Moderna asked the European Medicines Agency (EMA) for conditional marketing approval to use 50 micrograms of the vaccine in children aged 6 to 11 years.

The EMA said Wednesday that it expects to make a decision within about two months. Moderna is also seeking US approval for a vaccine for teens in June, awaiting a decision by the US Food and Drug Administration.

“The current assessment timeline is expected to take about two months, unless additional information or analysis is needed,” EMA said in a statement.

Reuters contributed to this report.

From NTD

Lorenz Duchan